Figure 2.
Figure 2. Acquisition of in vivo migratory abilities and CCR7 expression by IFN-λ–treated DCs. Control PBS, untreated iDCs, or iDCs treated for 24 hours with IFN-β, IFN-λ, or LPS were intravenously injected into SCID/Bg mice; DNA from lymph nodes and spleens were extracted after 8 or 24 hours. Human alu repetitive sequences were analyzed qualitatively by PCR (A) and quantitatively by real-time PCR (B) as a ratio with the quantification of a murine gene (see “Materials and methods”). Results are the means (95% confidence limits) of triplicate experiments performed on a single mouse for each condition tested. (C) Analysis of chemokine receptor CCR7 expression by flow cytometry. iDCs were treated for 24 hours with IFNs or LPS (gray lines); isotopic controls are indicated by filled surfaces. Results presented are from a single blood donor and are representative of results obtained with cells from 7 blood donors.

Acquisition of in vivo migratory abilities and CCR7 expression by IFN-λ–treated DCs. Control PBS, untreated iDCs, or iDCs treated for 24 hours with IFN-β, IFN-λ, or LPS were intravenously injected into SCID/Bg mice; DNA from lymph nodes and spleens were extracted after 8 or 24 hours. Human alu repetitive sequences were analyzed qualitatively by PCR (A) and quantitatively by real-time PCR (B) as a ratio with the quantification of a murine gene (see “Materials and methods”). Results are the means (95% confidence limits) of triplicate experiments performed on a single mouse for each condition tested. (C) Analysis of chemokine receptor CCR7 expression by flow cytometry. iDCs were treated for 24 hours with IFNs or LPS (gray lines); isotopic controls are indicated by filled surfaces. Results presented are from a single blood donor and are representative of results obtained with cells from 7 blood donors.

Close Modal

or Create an Account

Close Modal
Close Modal